In his first press conference as president-elect, Donald Trump insisted pharma was “getting away with murder” due to expensive drug prices.
The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
Alexion names former Baxalta head as CEO; U.S. dollar drops after AHCA-fail; EMA advises suspension of 300 generic drugs by Indian drugmaker
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Per the credit ratings agency, more uninsured Americans will lead to less demand for healthcare services and treatments.
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Novartis’ Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role